Efficacy News and Research

RSS

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health, Inc., has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

16 Nov 2013

Research could refine next generation of drugs to help treat dementia

A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.

15 Nov 2013

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

The world should aim to have vaccines which reduce malaria cases by 75%, and are capable of eliminating malaria, licensed by 2030, according to the updated 2013 "Malaria Vaccine Technology Roadmap", launched today.

15 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

15 Nov 2013

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

15 Nov 2013

Scientists discover new drug mechanism to reduce risk of infections

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.

15 Nov 2013

Lower doses of antimalarial drug effective in reducing malaria transmission

Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical Medicine researchers.

15 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

NeuroPace RNS System gets premarket approval from FDA for treatment of partial onset seizures

NeuroPace, Inc. today announced that the U.S. Food and Drug Administration has granted premarket approval for the NeuroPace RNS System, a treatment for adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs.

14 Nov 2013

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.

From Medtronic 14 Nov 2013

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

14 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Nutranomics to distribute Nutriband transdermal delivery system in North America

Nutranomics, Inc. is pleased to announce that the Company has acquired the exclusive North American sales and distribution rights to the Nutriband delivery system, an innovative and commercialized health supplement transdermal patch system currently available in Europe.

14 Nov 2013

New center launched to increase efficacy, reduce costs at four health care providers across Indiana

In response to rising national health care costs, the Indiana University School of Medicine and Indiana Clinical and Translational Sciences Institute have launched a new center to increase efficacy and reduce costs at four major health care providers across Indiana.

14 Nov 2013

Hemianopia patients confirm prism benefits

Results from a crossover trial confirm anecdotal reports that patients with homonymous hemianopia benefit from wearing peripheral prism glasses.

13 Nov 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

New data presented at the 6th Pan Asian Committee for Treatment and Research in Multiple Sclerosis, show positive preliminary results from PERSIST, a 12-month, Phase 4 clinical study of once weekly Avonex Pen for patients with relapsing-remitting multiple sclerosis.

13 Nov 2013

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

13 Nov 2013

Efficacy News and Research

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

Research could refine next generation of drugs to help treat dementia

New Malaria Vaccine Technology Roadmap aims to identify second generation malaria vaccines

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Scientists discover new drug mechanism to reduce risk of infections

Lower doses of antimalarial drug effective in reducing malaria transmission

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

NeuroPace RNS System gets premarket approval from FDA for treatment of partial onset seizures

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Nutranomics to distribute Nutriband transdermal delivery system in North America

New center launched to increase efficacy, reduce costs at four health care providers across Indiana

Hemianopia patients confirm prism benefits

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News